Financials data is unavailable for this security.
View more
Year on year Chugai Pharmaceutical Co Ltd 's revenues fell -11.78% from 1.26tn to 1.11tn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 374.43bn to 325.47bn, a -13.08% decrease.
| Gross margin | 69.46% |
|---|---|
| Net profit margin | 32.74% |
| Operating margin | 44.85% |
| Return on assets | 18.25% |
|---|---|
| Return on equity | 21.75% |
| Return on investment | 21.50% |
More ▼
Cash flow in JPYView more
In 2023, Chugai Pharmaceutical Co Ltd increased its cash reserves by 106.45%, or 236.51bn. The company earned 409.92bn from its operations for a Cash Flow Margin of 36.88%. In addition the company used 37.29bn on investing activities and also paid 139.33bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1,064.55 |
|---|---|
| Tangible book value per share | 1,052.19 |
More ▼
Balance sheet in JPYView more
| Current ratio | 5.09 |
|---|---|
| Quick ratio | 4.17 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in JPY
SmartText is unavailable
| Div yield(5 year avg) | 1.65% |
|---|---|
| Div growth rate (5 year) | 27.23% |
| Payout ratio (TTM) | 37.54% |
| EPS growth(5 years) | 28.59 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 8.57 |
More ▼
